USA: Low-dose intralesional cemiplimab demonstrated an acceptable safety profile and promising tumour response in patients with early-stage cutaneous squamous cell carcinoma (CSCC), a phase 1 study published in the Journal of the American Academy of Dermatology has shown. The findings suggest that injecting immunotherapy directly into the tumour may offer a potential non-surgical treatment approach for selected patients with early-stage skin cancer.

The study was conducted by Michael Migden, MD, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, and colleagues.
CSCC is a common form of skin cancer, and surgical excision remains an established treatment option. However, non-surgical alternatives for patients with small, early-stage tumours measuring 1–2 cm remain limited. Cemiplimab, an immune checkpoint inhibitor targeting programmed death 1 (PD-1), has demonstrated activity against CSCC. Researchers investigated whether administering lower doses directly into the tumour could achieve tumour control while maintaining an acceptable safety profile.
The open-label, phase 1 pilot study (NCT03889912) evaluated intralesional cemiplimab through dose-escalation and expansion cohorts. A single tumour lesion was treated in each participant. During dose escalation, patients received weekly injections of 5 mg, 15 mg or 44 mg for 12 weeks. Subsequently, two expansion cohorts received 5 mg intralesional cemiplimab either weekly or once every two weeks for six weeks.
Tumour response was evaluated visually at Weeks 7 and 13, followed by surgical excision at Week 13 to assess pathological response.
The analysis revealed the following findings:
  • Study population: A total of 41 patients participated in the trial evaluating intralesional cemiplimab for early-stage CSCC.
  • Safety profile: Treatment was generally well tolerated. In both expansion cohorts, treatment-emergent adverse events were limited to Grade 1 or 2, with no higher-grade events reported.
  • Visual tumour response: At Week 13, complete visual response was achieved in 58.3% of patients receiving weekly injections in Cohort A and 41.7% of those receiving injections every two weeks in Cohort B.
  • Pathological response: Complete pathological response rates at Week 13 were 58.3% in Cohort A and 66.7% in Cohort B, indicating no detectable residual tumour in the assessed surgical specimens.
The researchers acknowledged that the limited sample size restricts the generalizability of the findings. Additionally, differences in intralesional administration could have influenced treatment delivery and response.
The investigators concluded that low-dose intralesional cemiplimab demonstrated encouraging activity and acceptable tolerability in early-stage CSCC. The findings support further investigation of the 5 mg weekly regimen as a potential non-surgical treatment strategy. Larger studies will be necessary to establish its effectiveness, safety and suitability for routine clinical practice.
Reference:
Migden, M., Ibrahim, S. F., Strasswimmer, J., Zeitouni, N., Rogers, G. S., DeSimone, J., Kheterpal, M., Visich, J. E., Han, H., Yoo, S., Seebach, F., Lowy, I., Cristea, M., & Fury, M. (2026). Intralesional cemiplimab for patients with early-stage cutaneous squamous cell carcinoma: Results from a dose-escalation study with expansion cohorts. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.10.075
Tags:    
Article Source : Journal of the American Academy of Dermatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .